Announcement PDF ABN 16 165 160 841 ASX RELEASE 7 November 2024 Section 708A(5)(e) Notice – Allotment of 67,723,015 Shares Amplia Therapeutics Limited (“ATX” or “the Company”) has today completed an allotment of 67,723,015 ordinary fully paid shares at the Offer Price of $0.115 per share in completion of an institutional placement (Placement) as part of a $13m Capital Raise announced 30 October 2024. All of the shares issued will rank pari passu with existing ATX ordinary shares. In accordance with Section 708A (5)(e) of the Corporations Act 2001 (Act), the Company gives notice that: • The Company has issued these shares without disclosure to investors under Part 6D.2 of the Act; • As at the date of this notice, the Company has complied with: - • the provisions of Chapter 2M of the Act as they apply to the Company; and Sections 674 and 674A of the Act; and As at the date of this notice there is no excluded information (as defined in Sections 708A (7) and 708A(8) of the Act) which is required to be disclosed by the Company. - End - This ASX announcement was approved and authorised for release by the Company Secretary. About Narmafotinib Narmafotinib (AMP945) is the Company’s best-in-class inhibitor of the protein FAK, a protein overexpressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study, and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy. About the ACCENT Trial The ACCENT trial is entitled ‘A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients’. The ACCENT trial explores the use of narmafotinib in combination with standard-of-care chemotherapy of gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, identified a 400 mg oral daily dose of narmafotinib, given in the days preceding regular chemotherapy infusion, as safe and well tolerated. Level 21, 90 Collins Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com This second stage (Phase 2a), of the trial is designed to assess drug efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed. More information about the ACCENT trial, including a list of participating sites, can be found via the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn.